Trial reportAmerican journal of hematology2020
Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.
Abstract readClinical TrialLetterMulticenter Study
In one paragraph
Trial report in American journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Primary and secondary stroke prophylaxis in children with sickle cell anemia: a meta-analysis.Blood advances · 2026Pooled it
- Pooled it
- Stroke prevention in Hispanic children with sickle cell anemia: the SACRED trial.Blood advances · 2025Trial
- Hydroxyurea to prevent brain injury in children with sickle cell disease (HU Prevent)-A randomized, placebo-controlled phase II feasibility/pilot study.American journal of hematology · 2024Trial
- Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial.The Lancet. Haematology · 2023Trial
- Trial
- Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa.Acta haematologica · 2023Trial
- Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.The Lancet. Haematology · 2022Trial
- Capacity Building for Primary Stroke Prevention Teams in Children Living With Sickle Cell Anemia in Africa.Pediatric neurology · 2021Trial
- Initial low and moderate dose of hydroxyurea has a durable impact on primary stroke prevention in low-income settings.Blood advances · 2026Article
- Review
- Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations.Blood advances · 2026Article
- Hydroxyurea to decrease stroke risk in children with sickle cell anemia: a systematic review and meta-analysis.Blood global hematology · 2025Article
- The feasibility of pharmacokinetic-based dosing of hydroxyurea for children with sickle cell anaemia in Uganda: Baseline results of the alternative dosing and prevention of transfusions trial.British journal of clinical pharmacology · 2025Article
- Red Blood Cell Exchange Apheresis in the Management of Acute Chest Syndrome: Case Study at Greater Accra Regional Hospital (Ghana)- Bone Marrow Transplant Unit (BMT-Ghana).Clinical case reports · 2025Article
- The feasibility of pharmacokinetic-based dosing of hydroxyurea for children with sickle cell anaemia in Uganda: Baseline results of the alternative dosing and prevention of transfusions trial.British journal of clinical pharmacology · 2025Article
- Pharmacokinetic-Guided Hydroxyurea to Reduce Transfusions in Ugandan Children with Sickle Cell Anemia: Study Design of the Alternative Dosing And Prevention of Transfusions Trial.Acta haematologica · 2025Article
- Article
- Identifying strokes in Nigerian children with sickle cell disease as part of clinical trials: training curriculum for healthcare professionals in low-income settings.Frontiers in stroke · 2024Article
- Pain Frequency and Health Care Utilization Patterns in Women with Sickle Cell Disease Experiencing Menstruation-Associated Pain Crises.Journal of women's health (2002) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Najibah A GaladanciDepartment of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama.
Shehu U AbdullahiDepartment of Pediatrics, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria.
Shehi Ali AbubakarDepartment of Radiology, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria.
Binta Wudil JibirDepartment of Pediatrics, Hasiya Bayero Children's Hospital, Kano, Nigeria.
Hauwa AminuMurtala Mohammed Specialist Hospital, Kano, Nigeria.
Aliyu TijjaniMurtala Mohammed Specialist Hospital, Kano, Nigeria.
Muhammad S AbbaDepartment of Pharmacy, Aminu Kano Teaching Hospital, Kano, Nigeria.
Musa A TabariDepartment of Radiology, Barau-Dikko Teaching Hospital, Kaduna, Nigeria.
Aisha GaladanciDepartment of Hematology, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria.
Awwal Musa BorodoDepartment of Medicine, Murtala Muhammad Specialist Hospital, Kano, Nigeria.
Raymond BelonwuDepartment of Pediatrics, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria.
Auwal S SalihuDepartment of Psychiatry, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria.
Mark RodeghierRodeghier Consultants, Chicago, Illinois.
Djamila L GhafuriDivision of Hematology and Oncology, Department of Pediatrics, Vanderbilt-Meharry of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, Tennessee.
Brittany V Covert C GreeneDivision of Hematology and Oncology, Department of Pediatrics, Vanderbilt-Meharry of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, Tennessee.
Kathleen NevilleDepartment of Pediatrics, Divisions of Pediatric Hematology-Oncology and Clinical Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Adetola A KassimDivision of Hematology and Oncology, Department of Medicine Vanderbilt University School of Medicine, Nashville, Tennessee.
Fenella J KirkhamDepartment of Pediatrics, University College of London, Great Ormond Street Institute of Child Health, London, UK.ORCID 0000-0002-2443-7958
Lori C JordanDivision of Pediatric Neurology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0001-7240-0415
Muktar H AliyuVanderbilt Institute for Global Health, Nashville, Tennessee.
Michael R DeBaunDivision of Hematology and Oncology, Department of Pediatrics, Vanderbilt-Meharry of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-0574-1604
Funding
Primary prevention of stroke in children with SCD in Sub-Saharan Africa IIR01NS094041 · NINDS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ABDULLAHI, SHEHU UMAR, ALIYU, MUKTAR HASSAN · 2015 to 2019
$5.4MNational Institutes of Health/National Institute of Neurological Disorder and Stroke 1R01NS094041NINDS NIH HHS R01 NS094041
Abstract
PubMed holds no abstract for this paper.
Indexed as
Anemia, Sickle CellChildChild, PreschoolFemaleHumansHydroxyureaMaleNigeriaStrokeHydroxyurea
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.